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Acute renal failure (ARF) is a common complication in patients
with decompensated cirrhosis. The traditional diagnostic criteria
of renal failure in these patients were proposed in 1996 [1] and
have been reﬁned in subsequent years [2]. According to these cri-
teria, ARF is deﬁned as an increase in serum creatinine (sCr) of
P50% from baseline to a ﬁnal value >1.5 mg/dl (133 lmol/L).
However, the threshold value of 1.5 mg/dl (133 lmol/L) sCr to
deﬁne renal failure in patients with decompensated cirrhosis
has been challenged [3,4]. In addition, the timeframe to
distinguish acute from chronic renal failure has not been clearly
identiﬁed, the only exception being type 1 hepatorenal syndrome
(HRS). Meanwhile, new deﬁnitions for ARF, now termed acute
kidney injury (AKI), have been proposed and validated in patients
without cirrhosis [5–7]. Recently these new criteria were
also proposed and applied in the diagnosis of AKI in patients with
cirrhosis [3,8–15]. Thus, in December 2012, the InternationalJournal of Hepatology 20
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Open access under CC BY-NC-ND license.Club of Ascites (ICA) organised a consensus development meeting
in Venice, Italy, in order to reach a new deﬁnition of AKI in
patients with cirrhosis. The discussion among the experts
continued thereafter for 2 years, both online and through several
meetings, between those experts who had different positions on
crucial points on the subject. This paper reports the scientiﬁc
evidence supporting the ﬁnal proposal of a new approach to
the diagnosis and treatment of this condition, on which the
experts agreed.Diagnostic criteria of AKI and their application in patients
with cirrhosis
AKI is deﬁned as an acute signiﬁcant reduction in the glomerular
ﬁltration rate (GFR). sCr remains the most practical biomarker of
renal function in patients with ARF (with or without cirrhosis).
However, sCr as a biomarker of renal function has many limita-
tions in clinical practice since it is inﬂuenced by body-weight,
race, age, and gender. The use of sCr in patients with cirrhosis
is also affected by: (1) decreased formation of creatinine from
creatine in muscles, secondary to muscle wasting [16]; (2)
increased renal tubular secretion of creatinine [17]; (3) the
increased volume of distribution in cirrhosis that may dilute
sCr; (4) interference with assays for sCr by elevated bilirubin
[18]. As a consequence, measurement of sCr in patients with
cirrhosis overestimates GFR or kidney function. Therefore, the15 vol. 62 j 968–974
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use of a ﬁxed threshold of sCr at 1.5 mg/dl (133 lmol/L) to deﬁne
AKI in cirrhosis [1,2] is problematic, because of two crucial prob-
lems. The ﬁrst is that an sCr value of 1.5 mg/dl (133 lmol/L) often
signiﬁes that GFR is markedly decreased (to 30 ml/min) [19];
secondly, the ﬁxed threshold does not take into account the
dynamic changes in sCr that occur in the preceding days or
weeks, which are needed to distinguish between acute and
chronic kidney injury. Since the use of a single value of sCr is
not sufﬁcient to diagnose AKI, a dynamic deﬁnition referring to
an acute increase of sCr to P50% from baseline to a ﬁnal value
P1.5 mg/dl (133 lmol/L) has been used in several clinical studies
in patients with cirrhosis (Table 1). AKI, as deﬁned by these crite-
ria, was a strong predictor of in-hospital mortality in patients
with cirrhosis [20–23]. In recent years, diagnostic criteria have
been proposed for the diagnosis of ARF in non-cirrhotic patients,
now termed AKI. In particular, two separate bodies developed
and published two consensus deﬁnitions of AKI: the Acute Dialy-
sis Quality Initiative group for the Risk, Injury, Failure, Loss of
Renal Function and End-Stage Renal Disease (RIFLE) criteria;
and the Acute Kidney Injury Network (AKIN) group for the AKIN
criteria (Table 1) [5,6]. More recently, a panel of experts has sug-
gested combining part of the AKIN criteria (increase of sCr of
0.3 mg/dl (26.5 lmol/L) within 48 h or by P50% from baseline
together with a reduction in urine output to <0.5 ml/kg/h for
>6 h) with part of the RIFLE criteria (increase of sCrP50% within
1 week or a reduction in GFR by >25% together with a reductionTable 1. Current diagnostic criteria for acute kidney injury (AKI) in the general pop
RIFLE criteria AKIN criteria
Diagnostic 
criteria
Increase in SCr to ≥1.5 times 
baseline, within 7 days; or 
GFR decrease >25%; or 
Urine volume <0.5 ml/kg/h for 
6 h
Increase in sCr by ≥0.3 mg/
dl (26.5 μmol/L) within 48 
hours; or
Increase in sCr ≥1.5 times 
baseline within 48 hours; or 
Urine volume <0.5 ml/kg/h 
for 6 h
Staging Risk:
sCr increase 1.5-1.9 times 
baseline; or
GFR decrease 25-50%; or 
Urine output <0.5 ml/kg/h for 
6 h
Stage 1:
sCr increase 1.5-1.9 
times baseline; or
sCr increase ≥0.3 mg/dl 
(26.5 μmol/L); or
Urine output <0.5 ml/kg/h 
for 6 h
Injury:
sCr increase 2.0-2.9 times 
baseline; or
GFR decrease 50-75%; or 
Urine output <0.5 ml/kg/h for 
12 h
Stage 2:
sCr increase 2.0-2.9 times 
baseline; or
Urine output <0.5 ml/kg/h 
for 12 h
Failure:
sCr increase ≥3.0 times 
baseline; or
GFR decrease 50-75%; or 
sCr increase ≥4.0 mg/dl 
(353.6 μmol/L) with an acute 
increase of at least 0.5 mg/dl 
(44 μmol/L); or
Urine output <0.3 ml/kg/h for 
≥24 h; or
Anuria for ≥12 h
Stage 3:
sCr increase 3.0 times 
baseline; or
sCr increase ≥4.0 mg/dl 
(353.6 μmol/L) with an 
acute increase of at least 
0.5 mg/dl (44 μmol/L); or 
Urine output <0.3 ml/kg/h 
for ≥24 h; or 
Anuria for ≥12 h
AKIN, Acute Kidney Injury Network; GFR, glomerular ﬁltration rate; KDIGO, Kidney Dise
disease; sCr, serum creatinine.
Journal of Hepatology 201in urine output to <0.5 ml/kg/h for >6 h), thus leading to the
proposal of the Kidney Disease Improving Global Outcome (KDI-
GO) criteria [7] (Table 1).
However, the use of a reduction of urine output in patients
with cirrhosis and ascites as a diagnostic criterion is a problem,
since these patients are frequently oliguric with avid sodium
retention and yet may maintain a relatively normal GFR [24].
Conversely, these patients may have an increased urine output
because of diuretic treatment. Thus, urine collection is often inac-
curate in clinical practice and the use of kinetic changes in sCr
becomes the crux of the deﬁnition for the diagnosis of AKI in cir-
rhosis. The main differences between these new criteria over the
conventional criteria in patients with cirrhosis are the following:
(1) an absolute increase in sCr is considered; (2) the threshold of
sCrP1.5 mg/dl (133 lmol/L) is abandoned; and (3) a staging sys-
tem of AKI, based on a change in sCr over a slightly longer time
frame, arbitrarily set at 1 week to enable assessment for progres-
sion of stage (modiﬁed from AKIN staging) as well as a regression
of stage (Table 1). AKIN criteria have been shown to be a good
predictor of mortality in large cohorts of hospitalised cirrhotic
patients, including those in intensive care units [25] and the crit-
ically ill [26]. More recently, AKI as diagnosed with AKIN criteria
has been shown to be associated with increased mortality in
patients with cirrhosis who were hospitalised in regular wards
in an AKIN stage-dependent fashion [8–13,15]. Further, the pro-
gression of AKI through stages (e.g., from stage 1 to 2 or stage 2ulation and in patients with cirrhosis.
KDIGO criteria Conventional criteria for 
diagnosis of AKI in cirrhosis
Increase in sCr by ≥0.3 mg/dl 
(26.5 μmol/L) within 48 h; or 
Increase in SCr to ≥1.5 times 
baseline, which is known or 
presumed to have occurred 
within the prior 7 days; or 
Urine volume <0.5 ml/kg/h for 
6 h
A percentage increase in 
sCr of 50% or more to a final 
value of sCr >1.5 mg/dl (133 
μmol/L)
Stage 1:
sCr increase 1.5-1.9 times 
baseline; or
Cr increase ≥0.3 mg/dl (26.5 
μmol/L); or
Urine output <0.5 ml/kg/h for 
6-12 h
Not provided
Stage 2:
sCr increase 2.0-2.9 times 
baseline; or
Urine output <0.5 ml/kg/h for 
≥12 h
Stage 3:
sCr increase 3.0 times baseline; or
sCr increase to ≥4.0 mg/dl 
(353.6 μmol/L); or
Initiation of renal replacement 
therapy; or
Urine output <0.3 ml/kg/h for 
≥24 h; or
Anuria for ≥12 h
ase Improving Global Outcome; RIFLE, Risk, Injury, Failure, Loss, End stage renal
5 vol. 62 j 968–974 969
Position Paper
to 3) was strongly correlated with an increased mortality in these
patients [8–10]. Nevertheless, a comparison of the prognostic
accuracy of the conventional criteria and the new criteria in
patients with cirrhosis was considered crucial for the develop-
ment of a new algorithm for the management of AKI and was pro-
posed by the ICA in 2011 [3].
However, the cut-off value of 1.5 mg/dl (133 lmol/L) still
has important resonance with many clinicians. Two prospective
studies have recently shown that a cut-off value of sCr of
1.5 mg/dl (133 lmol/L) is useful to predict progression of AKI
and consequently the prognosis in patients with cirrhosis
[9,10]. Thus, an sCr P1.5 mg/dl (133 lmol/L) was the only pre-
dictive factor for progression of the initial AKI stage (AKI stage
at the ﬁrst fulﬁlment of AKIN criteria) to a higher AKI stage
during hospitalisation (peak AKI stage). Thereafter, it was also
shown that the cut-off value of sCr P1.5 mg/dl (133 lmol/L)
was important when patients with peak AKI stage 1 were
considered. In fact, patients with AKI stage 1 could be divided
into two groups: those whose peak sCr did not exceed 1.5 mg/
dl (stage 1-A), whose short term mortality might be similar to
those without AKI and in whom regression might occur more
frequently [9,10]; and those whose peak sCr exceeded
1.5 mg/dl (stage 1-B), whose short term mortality was higher
than those without AKI [9,10]. Patients with AKI stage 2 and
3 have the highest mortality [8–10]. However, whether these
observations can be generalised to all hospitalised patients
with cirrhosis should be assessed in future studies. In fact, as
far as the impact of peak AKI stage 1 on in-hospital mortality,
it has recently been observed that in patients who developed
AKI as a consequence of a bacterial infection, those with stage
1 AKI and a ﬁnal sCr 61.5 mg/dl (133 lmol/L) had a higher
short term mortality compared to those without AKI [13,27].
In addition, regarding regression of AKI stage, it has recently
been observed (in non-hospitalised patients) that despite reso-
lution of most AKI episodes in patients with advanced cirrhosis,
a gradual and signiﬁcant increase in sCr and a gradual reduc-
tion in mean arterial pressure were observed during follow-
up, associated with a signiﬁcant reduction in mid-term survival
compared with non-AKI patients [11]. Indeed, the main lessonTable 2. International Club of Ascites (ICA-AKI) new deﬁnitions for the diagnosis an
Subject Definition
Baseline sCr A value of sCr obtained in the previous 3 mon
with more than one value within the previous 
should be used.
In patients without a previous sCr value, the s
Definition of AKI • Increase in sCr ≥0.3 mg/dl (≥26.5 µmol/L) w
• A percentage increase sCr ≥50% from base
prior 7 days
Staging of AKI • Stage 1: increase in sCr ≥0.3 mg/dl (26.5 μ
• Stage 2: increase in sCr >2-fold to 3-fold fr
• Stage 3: increase of sCr >3-fold from base
mg/dl (26.5 μmol/L) or initiation of renal rep
Progression of AKI Progression
Progression of AKI to a higher stage and/or n
for RRT
Response to treatment No response Partial response
No regression of AKI Regression of AK
of sCr to ≥0.3 mg
the baseline valu
AKI, acute kidney injury; RRT, renal replacement therapy; sCr, serum creatinine.
970 Journal of Hepatology 201learnt from the application of AKIN criteria is that even a small
increase in sCr should be identiﬁed as early as possible for
potential early interventions.
Why do we need to change the conventional diagnostic
criteria for AKI?
A recent editorial on the topic of AKI in cirrhosis [28] asked the
question: ‘‘Should we change current deﬁnition and diagnostic
criteria of renal failure in cirrhosis?’’ Currently, studies on AKI
in patients with cirrhosis showed that AKI deﬁned by an abso-
lute increase in sCrP0.3 mg/dl (26.5 lmol/L) and/orP50% from
baseline is associated with a higher probability of the patients
being transferred to the intensive care unit, a longer hospital
stay, and an increased in-hospital as well as 90-day and
mid-term mortality [8–15]. On the basis of this evidence, all
the experts agreed that it was time to change our current
deﬁnition of renal failure by introducing a modiﬁed version of
the KDIGO criteria for the diagnosis of AKI in patients with
cirrhosis (Table 2). In the new ICA criteria for the diagnosis of
AKI, the use of urine output as one of the criteria has been
removed since it does not apply to patients with cirrhosis (ie,
many patients are oliguric but have preserved kidney function)
and it has never been investigated. Further, two other changes
to the KDIGO criteria were adopted, namely: (1) a sCr within
the last 3 months before admission is considered a baseline
value for the diagnosis of AKI when a value within the previous
7 days is not available; and (2) the calculation of the baseline
sCr by the reverse application of the Modiﬁcation of Diet in
Renal Disease (MDRD) formula, using an arbitrarily deﬁned
normal value of GFR of 75 ml/min/1.73 m2, was not included.
These two points are speciﬁcally discussed in the next section.
Deﬁnition of baseline serum creatinine for the diagnosis of
AKI
The ﬁrst step in applying the ICA-AKI criteria is to deﬁne a baseline
sCr. It has been stated that a renal disease process that results in a
change in sCr over several weeks cannot be deﬁned as AKI,d management of AKI in patients with cirrhosis.
ths, when available, can be used as baseline sCr. In patients 
3 months, the value closest to the admission time to the hospital 
Cr on admission should be used as baseline.
ithin 48 hours; or,
line which is known, or presumed, to have occurred within the
mol/L) or an increase in sCr ≥1.5-fold to 2-fold from baseline
om baseline
line or sCr ≥4.0 mg/dl (353.6 μmol/L) with an acute increase ≥0.3
lacement therapy
Regression
eed Regression of AKI to a lower stage
Full response
I stage with a reduction 
/dl (26.5 µmol/L) above 
e
Return of sCr to a value within 0.3 mg/
dl (26.5 µmol/L) of the baseline value
5 vol. 62 j 968–974
Stage 1 AKI#
Resolution Stable Progression
Close follow up
Futher treatment of AKI 
decided on a 
case-by-case basis§
Specific treatment for 
other AKI phenotypes
Response
Meets criteria of HRS
Vasocontrictors 
and albumin
YES
YES
NO
NO
Close monitoring
Remove risk factors (withdrawal of 
nephrotoxic drugs, vasodilators 
and NSAIDs, decrease/withdrawal 
of diuretics, treatment of infections*
when diagnosed), plasma volume 
expansion in case of hypovolemia
Withdrawal of diuretics 
(if not withdrawn 
already) and volume 
expansion with albumin 
(1 g/kg) for 2 days
Stage 2 and 3 AKI#
Fig. 1. Proposed algorithm for the management of acute kidney injury (AKI)
according to International Club of Ascites—AKI (ICA-AKI) classiﬁcation that
combines Kidney Disease Improving Global Outcomes (KDIGO) criteria and
conventional criteria in patients with cirrhosis and ascites.Most of the experts
had concerns about the use of vasoconstrictors in patients with AKI stage 1 and
sCr <1.5 mg/dl. For the deﬁnition of close follow-up, and/or case-by-case, see the
text. ⁄Treatment of spontaneous bacterial peritonitis should include albumin
infusion according to current guidelines. #Initial AKI stage is deﬁned as AKI stage
at the time of ﬁrst fulﬁlment of the AKI criteria. §No global consensus was reached
on this point. HRS, hepatorenal syndrome; NSAIDs, non-steroidal anti-inﬂamma-
tory drugs; sCr, serum creatinine.
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although itmay still represent an important clinical entity [7].Nev-
ertheless, as with any clinical scenario, the timeframe for the deﬁ-
nition of AKI is somewhat arbitrary, and it ismainly suitable for the
diagnosis of AKI in hospitalised patients using a sCr value on or
after admission as baseline (hospital-acquired AKI). However, as
in the general population, many patients with cirrhosis can
develop AKI before admission to hospital (community-acquired
AKI). Indeed, in previous studies where pre-admission values of
sCr were used as baseline, the rate of AKI was higher than in those
based on sCr on admission as baseline (47% vs. 26%) [9,10]. Thus,
the diagnosis of community-acquired AKI on admission is related
to two possible scenarios: (1) the patient with an available sCr
value before admission; and (2) the patient without an sCr value
before admission. The use of pre-admission values of sCr poses a
great dilemma: how far back can a baseline value of sCr be
retrieved and still be expected to be ‘valid’ for the deﬁnition of
AKI? In the general population, it is reasonable to assume that
sCr will be stable over several months or even years, so that an
sCr obtained 6 months or even 1 year previouslywould reasonably
reﬂect the patient’s premorbid baseline [7,29]. In patientswith cir-
rhosis, an application of a more rigorous time frame for the deﬁni-
tion of AKI seems even more important. In fact, in these patients,
impairment of renal function may progress gradually as they go
from a compensated to a decompensated state and thenmore rap-
idly as the decompensated state worsens. In addition, it should be
considered that almost all patients with cirrhosis and ascites
receive diuretics that can transiently impair renal function and,
thus, increase sCr.
Furthermore, it is important to emphasise the variability in sCr
measurements from laboratory to laboratory or even within the
same laboratory due to, for example, ﬂuctuations in serum biliru-
bin in patients with cirrhosis [30]. A sCr obtained <7 days before
admissionwould be the ideal condition to use the ICA-AKI criteria,
but this timeframe seems unfeasible in most cases. Thus, taking
into account the previous experiences, we conclude that use of
the last value of sCr within the last 3 months before admission
seems more feasible [10,13]. In this scenario, a community-
acquired AKI may be diagnosed in the case of an increase in sCr
P50% from the last sCr value (Table 2). For patients without an
available sCr before hospitalisation, the use of an estimated value
of sCr as the baseline, calculated by the reverse application of the
MDRD formula using a predetermined value of GFR (75 ml/min),
has been suggested for the general populationof patients [7]. How-
ever, it is well known that the MDRD formula is inaccurate in the
estimation of GFR in patients with cirrhosis, particularly in those
with ascites [31]. As a result, its reverse application in these
patients may only add further biases. Preliminary data from the
Padua centre suggest that a diagnosis of AKI based on an computed
value of sCr as baseline identiﬁes <25% of patientswith ameasured
GFR <60 ml/min on admission (Angeli P et al., unpublished obser-
vations). However, among patients without an sCr value before
admission, one scenario deserves speciﬁc mention, and that is
the case of the patient with an sCr P1.5 mg/dl (133 lmol/L) at
admission. The management of such a patient should be based
not only on a formal deﬁnitionof AKI, but also on clinical judgment.
Therefore, in a patient with impairment of renal function and a
clearly identiﬁable precipitating event, it would be reasonable to
assume that the renal failure represents AKI. Alternatively, the ini-
tial sCrmaybeused as thebaseline value, and if AKI criteria aremet
subsequently then the patient has AKI. This approach was com-
monly used previously for the diagnosis of type 1 HRS [32].Journal of Hepatology 201A new algorithm for the management of AKI in patients with
cirrhosis
According to the new ICA-AKI diagnostic criteria for AKI, we pro-
pose a new algorithm for the management of AKI in patients with
cirrhosis (Fig. 1). The algorithm is based on the new staging of AKI.
We recommend that patients with cirrhosis and ascites with
initial ICA-AKI stage 1 should be managed as soon as possible
with the following measures:
1) Review drug chart: review of all medications (including over-
the-counter (OTC) drugs), reduction or withdrawal of diuretic
therapy, withdrawal of all potentially nephrotoxic drugs, vaso-
dilators or non-steroidal anti-inﬂammatory drugs (NSAIDs).
2) Plasma volume expansion in patients with clinically sus-
pected hypovolaemia (with crystalloids or albumin or
blood (in patients who had AKI as a result of gastrointesti-
nal bleeding) according to clinical judgment).
3) Prompt recognition and early treatment of bacterial infec-
tions when diagnosed or strongly suspected.
Patients who respond with a return of sCr to a value within
0.3 mg/dl (26.5 lmol/L) of the baseline value should be followed
closely (assessment of sCr every 2–4 days during the hospitalisa-
tion and checked as outpatients at least every 2–4 weeks during
the ﬁrst 6 months after the discharge) for early identiﬁcation of
potential new episodes of AKI [11]. In those cases where there
is progression of the AKI stage, the patients should be treated
as patients who present with ICA-AKI stage 2 and 3. This treat-
ment should include the withdrawal of diuretics, if this had not
been previously implemented, as well as the expansion of plasma
volume with intravenous albumin at the dose of 1 g per kg
bodyweight per day for two consecutive days, in order to treat5 vol. 62 j 968–974 971
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pre-renal AKI and to allow differential diagnosis of AKI (Box 1).
The maximal dose per day of albumin should not exceed 100 g
as previously suggested [2]. Further management of patients
who do not respond to diuretic withdrawal and plasma volume
expansion will obviously depend on the ﬁnal diagnosis of the
AKI type and, pragmatically, on the differential diagnosis
between an HRS-AKI, an intrinsic AKI, and post-renal-AKI
(Box 1). Thus, another major contribution of this new algorithm
is to accelerate the differential diagnostic process among the dif-
ferent types of AKI. However, it should be highlighted that several
steps of this algorithm are not based on evidence but just on
experts’ opinion, and that it should be validated in future pro-
spective clinical studies. In particular, in patients with AKI stage
1 who do not respond but who do not progress to a higher stage,
no consensus was obtained among the experts on the speciﬁc
treatment. All experts agreed to treat these patients according
to the right side of the algorithm when the ﬁnal value of sCr is
P1.5 mg/dl (133 lmol/L). Some experts favour the treatment of
patients with AKI stake 1 and sCr <1.5 mg/dl (133 lmol/L) in
the same way. However, most of the experts did not agree on this
because they had concerns about the early use of vasoconstric-
tors (terlipressin or norepinephrine or midodrine plus octreotide)
in these patients in case of HRS-AKI. Thus, further clinical con-
trolled studies are needed to address this relevant issue. In the
meantime, decisions about the treatment of these patients should
be taken on a case-by-case basis evaluating the aetiology of AKI,
the presence or absence of precipitating factors, other organ fail-
ures, or comorbid conditions that may contra-indicate treatment.
Box 1. Diagnostic criteria of hepatorenal 
syndrome (HRS) type of acute kidney injury 
(AKI) in patients with cirrhosis
HRS-AKI
• Diagnosis of cirrhosis and ascites
• Diagnosis of AKI according to ICA-AKI criteria
• No response after 2 consecutive days of diuretic
withdrawal and plasma volume expansion with albumin
1 g per kg of body weight
• Absence of shock
• No current or recent use of nephrotoxic drugs (NSAIDs,
aminoglycosides, iodinated contrast media, etc.)
• No macroscopic signs of structural kidney injury*,
defined as:
- absence of proteinuria (>500 mg/day)
- absence of microhaematuria (>50 RBCs per high
power field),
- normal findings on renal ultrasonography
*Patients who fulﬁl these criteria may still have structural
damage such as tubular damage. Urine biomarkers will 
become an important element in making a more accurate 
differential diagnosis between HRS and acute tubular 
necrosis.
ICA, International Club of Ascites; NSAIDs, non-steroidal 
anti-inﬂammatory drugs; RBCs, red blood cells.972 Journal of Hepatology 201Why do we need to change the diagnostic criteria of HRS in
the setting of AKI?A major critical point in the management of AKI in patients with
decompensated cirrhosis is whether the diagnostic criteria of
type 1 HRS should be revised in light of the new deﬁnitions of
AKI. The current criteria include a time interval (2 weeks) over
which sCr must double to a value >2.5 mg/dl for the diagnosis
of type 1 HRS [1,2]. A revision of these criteria is needed because
the current deﬁnition of type 1 HRS does not allow physicians to
initiate potentially effective treatment, speciﬁcally vasoconstric-
tors and albumin, until the sCr increases to P2.5 mg/dl. Since it
has been observed that in patients with type 1 HRS, a higher
sCr at the beginning of treatment leads to a lower probability
of response to terlipressin and albumin, the most investigated
and effective treatment of type 1 HRS [33,34], it seems prudent
not to wait until the sCr increases beyond 2.5 mg/dl before start-
ing the treatment. According to the new proposed algorithm,
when AKI is characterised by an initial ICA-AKI stage 2 or 3 or
by progression of the initial stage despite general therapeutic
measures, patients who meet all other diagnostic criteria of
HRS provided by the previous deﬁnition [2] should receive vaso-
constrictors and albumin, irrespective of the ﬁnal value of sCr.
This makes it possible to remove a barrier to the achievement
of a pharmacological response that was linked to the rigid sCr
cut-off value of >2.5 mg/dl in the deﬁnition of type 1 HRS. The
potential advantage of the algorithm is that its application may
allow earlier treatment of patients with type 1 HRS, leading to
a better outcome as compared with the current approach. How-
ever, we lack studies where vasoconstrictors were used in the
treatment of HRS with lower values of sCr, and caution should
be exercised in the use of vasoconstrictors in these patients pend-
ing further controlled trials.
Nevertheless, all the experts agreed on the removal of a ﬁxed
cut-off value of sCr from the diagnostic criteria of HRS. This is
the only change that they wanted to introduce in the current diag-
nostic criteria for HRS. As a consequence, all the remaining criteria
aremaintained (Box 1). However, these criteria do not rule out the
possibility of renal parenchymal damage [35]. Thus, all the
experts agreed on the potential role of new urinary biomarkers
in the differential diagnosis of the different types of AKI in patients
with cirrhosis. Several urinary biomarkers of tubular damage,
such as neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule-1 (KIM-1) interleukin-18 (IL-18), and liver fatty
acid-binding protein (L-FABP), have been discovered in recent
years. Preliminary experiences from Europe and the USA showed
that the use of NGAL [36] and/or the combination of urinary bio-
markers (NGAL, KIM-1, IL-18, L-FABP and albuminuria) [37] may
be useful in the differential diagnosis of AKI in patients with cir-
rhosis. These ﬁndings need to be conﬁrmed in future studies.
The removal of a ﬁxed cut-off value of sCr from the diagnostic
criteria of HRS in the setting of AKI has important implications in
the management of these patients. Thus, there is a need to change
the deﬁnition of response to the pharmacologic treatment of HRS.
Full response will be deﬁned by return of sCr to a value within
0.3 mg/dl (26.5 lmol/L) of the baseline value. Partial responses
will be deﬁned by a regression of at least one AKI stage with a fall
in the sCr value to P0.3 mg/dl (26.5 lmol/L) above the baseline
value. Nevertheless, we should recognise that preliminary data
suggest that even a partial decrease of sCr from baseline may
be associated with improved short term survival, irrespective of5 vol. 62 j 968–974
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whether or not the patient achieves HRS reversal (sCr <1.5 mg/dl)
[38]. These data suggest that the degree of improvement in sCr
may be more relevant than achieving a ﬁnite level of renal
function.Conclusions and future perspectives
Based on the most recent studies on AKI in patients with cirrhosis
and ascites, a new algorithm for the management of AKI in these
patients is proposed for clinical practice and for future research.
The main innovative aspects of this new algorithm are the
following:
 The adoption of the main point derived from the applica-
tion of the KDIGO criteria in the deﬁnition of AKI in
patients with cirrhosis, namely, use of dynamic changes
of sCr.
 A more structured diagnostic process, in order to allow a
rational application of the therapeutic resources, avoiding
potentially undesirable consequences of overtreatment of
AKI as a result of indiscriminant use of KDIGO criteria.
 The deﬁnitive removal of any cut-off value of sCr from the
criteria for diagnosis of HRS in the setting of AKI, but
maintaining the remaining previous criteria (Box 1).
Several issues remain to be addressed: (1) the impact of the
management of AKI according to the new algorithm on the out-
come of these patients should be tested in future prospective
studies; and (2) the role of the new biomarkers of renal tubular
damage in predicting the progression and prognosis of AKI, and
in the differential diagnosis of the different types of AKI [36,37].
In summary, the results of the latest consensus conference of
the ICA introduces a new dynamic deﬁnition of AKI in patients
with cirrhosis, on which a new treatment algorithm is based, rep-
resenting a substantial change from the traditional criteria used
until now in the deﬁnition of AKI and type 1 HRS.Financial support
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